ISSN:1533-029X    

出版商:OVID    

年代:2002

数据来源: OVID

摘要:

&NA;The objective of this study was to determine if heparin or ethylenediaminetetraacetic acid (EDTA) affected whole‐blood glucose measurements obtained with test strips and common handheld meter systems. Lithium heparin (15 USP units/mL), potassium (K2) EDTA (1.8 mg/dL), and no‐additive aliquots of venous blood from fifty‐five diabetic patients were tested using four handheld glucose meter systems: the SureStep Pro and the One Touch II (Lifescan, Milpitas, CA), the Precision PCx (Abbott Laboratories, MediSense Products, Bedford, MA), and the Accu‐Chek Comfort Curve (Roche Diagnostics, Indianapolis, IN), and a the YSI 2700 reference analyzer (Yellow Springs Instruments, Yellow Springs, OH). Coefficients of variation for within‐day and between‐day precision ranged from 1.4% to 6.8% for the glucose meter systems. Heparin and EDTA produce system‐specific effects. Anticoagulant versus no‐additive test strip comparisons showed that the SureStep Pro, with heparin and EDTA, and the Precision PCx, with EDTA, produced statistically significant negative mean paired differences. Heparin minimized the frequency of errors in glucose meter results. Heparinized samples produced the lowest frequency of discrepant meter results outside clinical error tolerances (± 15 mg/dL, glucose ≤ 100 mg/dL; ± 15%, glucose > 100 mg/dL) when compared with YSI 2700 reference results for paired samples. Specimen restrictions arise from anticoagulant selection, hematocrit range, physiological factors, and processing time. To reduce the potential for medical errors, the relative effects of different specimen anticoagulants should be considered carefully when conducting comparison studies, planning clinical applications, and interpreting glucose results.

ISSN:1533-029X    

出版商:OVID    

年代:2002

数据来源: OVID

摘要:

&NA;The NPT7 (Radiometer Medical A/S, Copenhagen, Denmark) point of care blood gas analyzer was evaluated in a tertiary care academic institution. The NPT7 demonstrated comparable precision to the ABL720 analyzers (coefficients of variation (CV) range = 0 to 4.9% and 0 to 7.8% for the NPT7 and ABL720 respectively). Correlation was excellent with regression slopes (0.88 to 1.05), intercepts (−2.76 to +7.60) and correlation coefficients (r = 0.9287 to 0.9980) (CV for duplicate differences range = 0.07 to 6.3% and 0.04 to 5.0% for the NPT7 and ABL720 analyzers excluding carboxyhemoglobin, methemoglobin, and deoxyhemoglobin analytes which were primarily in a low normal range). The internal QualityGuard system detected more errors (average 22 failures per analyzer) than traditional liquid controls (3 events). QualityGuard was able to monitor the entire analytical process and substitute for liquid controls in guaranteeing the quality of test results. With no required maintenance and intuitive operator interface, the NPT7 has application in a variety of settings.

ISSN:1533-029X    

出版商:OVID    

年代:2002

数据来源: OVID

摘要:

&NA;Community‐based screening for colorectal cancer can be effective when patient acceptance is high. Understanding the risks and benefits of screening, and the willingness of the physician to communicate this information to the patient, can be a positive influence on patient acceptance. In this nonrandomized retrospective observational study, we examined the results of offering screening to a group of patients attending the Palo Alto Medical Foundation in 1996.Average risk patients, (age 50 to 88 years, 53% female), were offered annual fecal occult blood testing (FOBT). A medical history was taken for all patients. Patients with positive FOBT findings were followed up with colonoscopy. Histological evaluation was done on all suspected neoplastic lesions (cancer and adenomas). Patients with negative FOBT results in 1996 remained under surveillance for 32 to 42 months.Of 11,501 patients who were offered screening, 75% participated in FOBT. There were 442 (5%) patients positive by FOBT. Advanced colonic neoplastic lesions were found in 78 patients. Of the 20 cancers detected during the surveillance period, 60% were early stage (Dukes A or B1). Other studies have shown that screening for colorectal cancer in community‐based settings can be effective in reducing mortality and incidence of the disease. This study extends these earlier reports, demonstrating that screening is most effective when patient acceptance is high.

ISSN:1533-029X    

出版商:OVID    

年代:2002

数据来源: OVID

摘要:

&NA;Colorectal cancer (CRC) is the third most common cancer in the United States. The disease occurs in both men and women in approximately equal numbers, with 135,000 new cases expected in 2001. More than 56,000 deaths from CRC are expected in 2001, making it the second most lethal cancer after lung cancer.1,2Colorectal cancer is most often a silent disease. Symptoms may not appear for as many as 10 to 15 years after the disease has begun. By the time symptoms do appear, the cancer is usually advancing rapidly, making effective treatment more difficult and chance of survival poor.3With good educational materials, planning, and a program approach, screening for CRC using the fecal occult blood test (FOBT) can be successful.4Studies have shown that screening for CRC using FOBT is cost effective.5,6Fecal occult blood test screening has been shown to be a practical strategy when compared with many other life‐saving health interventions.7

ISSN:1533-029X    

出版商:OVID    

年代:2002

数据来源: OVID

ISSN:1533-029X    

出版商:OVID    

年代:2002

数据来源: OVID

ISSN:1533-029X    

出版商:OVID    

年代:2002

数据来源: OVID

ISSN:1533-029X    

出版商:OVID    

年代:2002

数据来源: OVID

ISSN:1533-029X    

出版商:OVID    

年代:2002

数据来源: OVID

ISSN:1533-029X    

出版商:OVID    

年代:2002

数据来源: OVID